Vertex obtains an exclusive license to TreeFrog's C-StemTM  manufacturing technology in type 1 diabetes  TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells  BOSTON and BORDEAUX, France, April 23, 2024 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of ...

Could Vertex's growth story continue?Vertex Pharmaceuticals (VRTX 0.20%) has been through some ups and downs over the past few years. The big biotech disappointed investors when a couple of candidates outside of its specialty area of cystic fibrosis (CF) failed along the development path. But the company continued to impress with its CF products and their revenue growth as well as its advancement of other non-CF candidates in the pipeline.If you'd invested $10,000 in Vertex five years ago, you would have ac ...

Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has granted a rolling new drug application (NDA) submission for suzetrigine (formerly known as VX-548) in moderate-to-severe acute pain. The company has already initiated the rolling submission process and is on track to complete the NDA submission in the second quarter of 2024.Suzetrigine is an investigational orally administered selective NaV1.8 pain signal inhibitor. The rolling NDA submission is supported by encouraging results from the c ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $394.17, reflecting a -0.8% shift from the previouse trading day's closing. The stock fell short of the S&P 500, which registered a gain of 0.03% for the day. Elsewhere, the Dow gained 0.41%, while the tech-heavy Nasdaq added 0.12%.The drugmaker's stock has dropped by 3.41% in the past month, exceeding the Medical sector's loss of 5.81% and lagging the S&P 500's loss of 0.9%.Investors will be eagerly watching for the perfor ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) .Vertex currently has an average brokerage recommendation (ABR) o ...

Vertex just laid claim to an asset that might be very valuable.Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (VRTX -0.92%) announced it would purchase Alpine Immune Sciences (ALPN -0.05%) for $4.9 billion in cash in a deal that's set to close before the end of this quarter. The prized asset that Vertex will gain as part of this purchase is ALPN-303, a potential autoimmune treatment that's in phase 2 clinical trials.But there's a lot more to the deal's potential value ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run?Vertex Pharmaceuticals (VRTX -1.71%) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now hitting the $100 billion mark, has it become too expensive of an investment? Is it time for investors to consider other stocks instead, or can Vertex still be a good buy right now?Let's dive in and take a look.Why investor ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $397.58, marking a -1.71% move from the previous day. This change lagged the S&P 500's 0.95% loss on the day. At the same time, the Dow lost 1.09%, and the tech-heavy Nasdaq lost 0.84%.Prior to today's trading, shares of the drugmaker had lost 1.93% over the past month. This has was narrower than the Medical sector's loss of 3.76% and lagged the S&P 500's gain of 1.78% in that time.Market participants will be closely following the financ ...

This innovative machine rolls on.Biotech giant Vertex Pharmaceuticals (VRTX -0.82%) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive phase 3 results for exciting candidates.The drugmaker isn't stopping. Vertex is moving forward with another investigational medicine that could become a big deal somewhere down the road. Let's find out what it is and what it could mean for investors.Straight out of the playbookFirst, l ...